Li YD - Search Results

1

ALKBH1: emerging biomarker and therapeutic target for cancer treatment.

Xiao MZ, Fu JY, Bo LT, Li YD, Lin ZW, Chen ZS. Xiao MZ, et al. Among authors: li yd. Discov Oncol. 2024 Dec 20;15(1):816. doi: 10.1007/s12672-024-01696-5. Discov Oncol. 2024. PMID: 39704856 Free PMC article. Review.

2

Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells.

Li YD, Mao Y, Dong XD, Lei ZN, Yang Y, Lin L, Ashby CR Jr, Yang DH, Fan YF, Chen ZS. Li YD, et al. Front Oncol. 2020 Jun 26;10:932. doi: 10.3389/fonc.2020.00932. eCollection 2020. Front Oncol. 2020. PMID: 32676451 Free PMC article.

3

The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms.

Yazdanparast S, Huang Z, Keramat S, Izadirad M, Li YD, Bo L, Gharehbaghian A, Chen ZS. Yazdanparast S, et al. Among authors: li yd. Front Oncol. 2022 Jun 2;12:904637. doi: 10.3389/fonc.2022.904637. eCollection 2022. Front Oncol. 2022. PMID: 35719983 Free PMC article.

4

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.

Zhang L, Li Y, Hu C, Chen Y, Chen Z, Chen ZS, Zhang JY, Fang S. Zhang L, et al. Mol Cancer. 2022 Apr 22;21(1):103. doi: 10.1186/s12943-022-01524-w. Mol Cancer. 2022. PMID: 35459184 Free PMC article.

5

Nivolumab and relatlimab for the treatment of melanoma.

Chen XY, Li YD, Xie Y, Cao LQ, Ashby CR Jr, Zhao H, Chen ZS. Chen XY, et al. Among authors: li yd. Drugs Today (Barc). 2023 Feb;59(2):91-104. doi: 10.1358/dot.2023.59.2.3509756. Drugs Today (Barc). 2023. PMID: 36811409 Review.

6

The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, Hu C, Liao D, Zhang W, Chen ZS. Zhang L, et al. Mol Cancer. 2020 Jan 17;19(1):10. doi: 10.1186/s12943-019-1112-1. Mol Cancer. 2020. PMID: 31952518 Free PMC article.

7

ATP-binding cassette (ABC) transporters in cancer: A review of recent updates.

Wang JQ, Wu ZX, Yang Y, Teng QX, Li YD, Lei ZN, Jani KA, Kaushal N, Chen ZS. Wang JQ, et al. Among authors: li yd. J Evid Based Med. 2021 Sep;14(3):232-256. doi: 10.1111/jebm.12434. Epub 2021 Aug 13. J Evid Based Med. 2021. PMID: 34388310 Review.

8

Research progress in overcoming ibrutinib drug resistance.

Ma XY, Zhao M, Li YD, Chen Y, Wei L, Chen ZS. Ma XY, et al. Among authors: li yd. Drugs Today (Barc). 2022 Feb;58(2):85-94. doi: 10.1358/dot.2022.58.2.3360405. Drugs Today (Barc). 2022. PMID: 35188143

9

Combating antimicrobial resistance: the silent war.

Bo L, Sun H, Li YD, Zhu J, Wurpel JND, Lin H, Chen ZS. Bo L, et al. Among authors: li yd. Front Pharmacol. 2024 Feb 14;15:1347750. doi: 10.3389/fphar.2024.1347750. eCollection 2024. Front Pharmacol. 2024. PMID: 38420197 Free PMC article. Review.

10

RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells.

Dong XD, Lu Q, Li YD, Cai CY, Teng QX, Lei ZN, Wei ZH, Yin F, Zeng L, Chen ZS. Dong XD, et al. Among authors: li yd. J Transl Int Med. 2024 Jul 27;12(3):288-298. doi: 10.2478/jtim-2024-0011. eCollection 2024 Jun. J Transl Int Med. 2024. PMID: 39081282 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

740 results

Search Page

Filters